CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, announced that President and CEO Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, MD, Ph.D., will present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). The conference is being held at the Waldorf=Astoria Hotel in New York City. “We are actively developing our highly promising portfolio of oncology drug candidates for the treatment of multiple forms of cancer in eight ongoing or planned clinical trials,” said Mr. Kriegsman. “Since last May we have initiated clinical trials with bafetinib, tamibarotene and INNO-206 and we recently raised additional funds through a non-dilutive sale of RXi Pharmaceuticals common stock, which will support continued advancement of our programs. We plan to share our many developments and plans for the current year at this premier conference that is focused specifically on biotechnology.” A webcast and audio archive of the presentation will be available at www.cytrx.com and a replay of the webcast will also be available on the Company's Web site. About CytRx Corporation CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: bafetinib, tamibarotene and INNO-206. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer, and is conducting a pharmacokinetic clinical trial in brain cancer. With its tumor-targeting pro-drug candidate INNO-206, CytRx plans to initiate Phase 2 proof-of-concept clinical trials as a treatment for pancreatic cancer and soft tissue sarcomas, following an abbreviated safety trial. CytRx's pipeline also includes tamibarotene, which it is testing in patients with non-small-cell lung cancer and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL). For more information on the Company, visit http://www.cytrx.com.